Skip to main content
. Author manuscript; available in PMC: 2011 Jul 15.
Published in final edited form as: Cancer Res. 2010 Jun 29;70(14):5870–5879. doi: 10.1158/0008-5472.CAN-09-4281

Figure 1. Tubulin expression in HCN2 cells following drug treatment.

Figure 1

HCN2 cells were treated for 24h with paclitaxel (PTX, 50 nM), ixabepilone (50 nM), vincristine (VCR 25 nM, 50 nM and 100 nM), doxorubicin (DOX 400 ng/ml) and 5-fluorourocil (5-FU 5 mM). Immunoblots were hybridized with anti-tubulin (total α-tubulin and acetylated α-tubulin) and anti-p53 antibodies. Actin was used as a loading control.